

# Elizabeth Fox

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7180484/publications.pdf>

Version: 2024-02-01

94  
papers

3,647  
citations

201674

27  
h-index

138484

58  
g-index

94  
all docs

94  
docs citations

94  
times ranked

5372  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. <i>Neuro-Oncology</i> , 2022, 24, 655-664.	1.2	24
2	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. <i>European Journal of Cancer</i> , 2022, 160, 112-133.	2.8	24
3	Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3/ITD+</i> Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. <i>Journal of Clinical Oncology</i> , 2022, 40, 2023-2035.	1.6	36
4	Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute's Children's Oncology Group Pediatric MATCH Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2224-2234.	1.6	45
5	Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2235-2245.	1.6	21
6	Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i> , <i>ROS1</i> , or <i>ALK</i> aberrations (STARTRK-NG). <i>Neuro-Oncology</i> , 2022, 24, 1776-1789.	1.2	37
7	ACCELERATE – Five years accelerating cancer drug development for children and adolescents. <i>European Journal of Cancer</i> , 2022, 166, 145-164.	2.8	28
8	Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children's Oncology Group phase I consortium study. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	2
9	ADVL1514, a phase 1 study of ABI-009 (nab-sirolimus) in pediatric patients with recurrent or refractory solid tumors, including CNS tumors as a single agent and in combination with temozolomide and irinotecan: A Children's Oncology Group pediatric early-phase clinical trial network study. <i>Journal of Clinical Oncology</i> , 2022, 40, 10022-10022.	1.6	1
10	Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621). <i>Journal of Clinical Oncology</i> , 2022, 40, 3009-3009.	1.6	5
11	Tazemetostat in patients with tumors with alterations in EZH2 or the SWI/SNF complex: Results from NCI-COG Pediatric MATCH trial Arm C (APEC1621C). <i>Journal of Clinical Oncology</i> , 2022, 40, 10009-10009.	1.6	5
12	Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas. <i>European Journal of Cancer</i> , 2022, 173, 71-90.	2.8	9
13	Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. <i>Laryngoscope</i> , 2021, 131, E1941-E1949.	2.0	24
14	A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase Clinical Trial Network (PEPACTN). <i>Pediatric Blood and Cancer</i> , 2021, 68, e28892.	1.5	16
15	NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome. <i>JCO Precision Oncology</i> , 2021, 1, 204-214.	3.0	36
16	Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). <i>Clinical Cancer Research</i> , 2021, 27, 3543-3548.	7.0	59
17	Bromodomain and extra-terminal inhibitors: A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children: ACCELERATE. <i>European Journal of Cancer</i> , 2021, 146, 115-124.	2.8	10
18	A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 807-815.	2.3	3

#	ARTICLE	IF	CITATIONS
19	A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515). <i>Pediatric Blood and Cancer</i> , 2021, 68, e29065.	1.5	16
20	Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).. <i>Journal of Clinical Oncology</i> , 2021, 39, 10019-10019.	1.6	2
21	Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 359-365.	2.3	7
22	Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10018-10018.	1.6	0
23	Factors impacting enrollment on NCI-COG Pediatric MATCH trial treatment protocols.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10007-10007.	1.6	2
24	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29282.	1.5	3
25	Population Pharmacokinetics and Exposure-Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies. <i>Journal of Clinical Pharmacology</i> , 2021, , .	2.0	3
26	Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. <i>European Journal of Cancer</i> , 2021, 157, 198-213.	2.8	34
27	MEK Inhibition Demonstrates Activity in Relapsed, Refractory Patients with Juvenile Myelomonocytic Leukemia: Results from COG Study ADVL1521. <i>Blood</i> , 2021, 138, 3679-3679.	1.4	4
28	Pharmacokinetics of the disialoganglioside, GD2, a circulating tumor biomarker for neuroblastoma, in nonhuman primates. <i>Journal of Circulating Biomarkers</i> , 2021, 10, 26-29.	1.3	2
29	The ganglioside G <sub>D2</sub> as a circulating tumor biomarker for neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28031.	1.5	30
30	Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). <i>Pediatric Blood and Cancer</i> , 2020, 67, e28073.	1.5	52
31	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 121-133.	10.7	204
32	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. <i>Lancet Oncology</i> , The, 2020, 21, 271-282.	10.7	1,034
33	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children. <i>European Journal of Cancer</i> , 2020, 139, 135-148.	2.8	20
34	Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 829-840.	2.3	22
35	ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. <i>Cancer</i> , 2020, 126, 5303-5310.	4.1	17
36	Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 541-550.	10.7	202

#	ARTICLE	IF	CITATIONS
37	Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting. <i>Clinical Cancer Research</i> , 2020, 26, 4743-4747.	7.0	0
38	Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). <i>Clinical Cancer Research</i> , 2020, 26, 1213-1219.	7.0	38
39	Safety of Palbociclib in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoma: A Children's Oncology Group Pilot Study. <i>Blood</i> , 2020, 136, 20-21.	1.4	5
40	Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 107-107.	1.6	15
41	Dabrafenib + trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma: Safety and efficacy results.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10506-10506.	1.6	11
42	How to address challenges and opportunities in pediatric cancer drug development?. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 869-872.	5.0	1
43	Population pharmacokinetics of trabectedin in adolescent patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 707-717.	2.3	2
44	3488 A comparison between the Rolling 6 and 3+3 dose escalation study designs for phase 1 clinical trials. <i>Journal of Clinical and Translational Science</i> , 2019, 3, 30-31.	0.6	0
45	A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). <i>Clinical Cancer Research</i> , 2019, 25, 3229-3238.	7.0	61
46	PDCT-13. ENTRECTINIB IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS. <i>Neuro-Oncology</i> , 2019, 21, vi186-vi186.	1.2	0
47	Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10009-10009.	1.6	49
48	Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10011-10011.	1.6	25
49	Phase 1 study of pevonedistat (MLN4924) in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).. <i>Journal of Clinical Oncology</i> , 2019, 37, e21521-e21521.	1.6	1
50	A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614).. <i>Journal of Clinical Oncology</i> , 2019, 37, e21519-e21519.	1.6	3
51	Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin. <i>Oncologist</i> , 2018, 23, 762-e79.	3.7	28
52	Phase 1 trial of ontuxizumab (MORAb004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). <i>Pediatric Blood and Cancer</i> , 2018, 65, e26944.	1.5	19
53	Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. <i>Clinical Cancer Research</i> , 2018, 24, 753-765.	7.0	26
54	PDCT-04. PHASE 1 TRIAL OF WEE1 KINASE INHIBITOR AZD1775 COMBINED WITH RADIATION THERAPY FOR CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP PHASE 1 PILOT CONSORTIUM (ADVL1217). <i>Neuro-Oncology</i> , 2018, 20, vi201-vi201.		3

#	ARTICLE	IF	CITATIONS
55	New Agents, Emerging Late Effects, and the Development of Precision Survivorship. <i>Journal of Clinical Oncology</i> , 2018, 36, 2231-2240.	1.6	44
56	A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). <i>Cancer</i> , 2018, 124, 4548-4555.	4.1	35
57	A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). <i>Pediatric Blood and Cancer</i> , 2018, 65, e27066.	1.5	15
58	Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)-associated plexiform neurofibroma: A phase I/IIa study. <i>Journal of Clinical Oncology</i> , 2018, 36, 10504-10504.	1.6	35
59	KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1-positive advanced, relapsed or refractory solid tumor or lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 10525-10525.	1.6	10
60	Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN). <i>Journal of Clinical Oncology</i> , 2018, 36, 10537-10537.	1.6	20
61	G <sub>2</sub> as a circulating tumor biomarker (CTB) for neuroblastoma (NBL). <i>Journal of Clinical Oncology</i> , 2018, 36, 10538-10538.	1.6	2
62	Phase I multicenter trial of CUDC-907 in children and young adults with relapsed/refractory solid tumors, CNS tumors, and lymphomas. <i>Journal of Clinical Oncology</i> , 2018, 36, 10542-10542.	1.6	4
63	ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 10556-10556.	1.6	6
64	A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). <i>Pediatric Blood and Cancer</i> , 2017, 64, e26565.	1.5	11
65	Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26636.	1.5	23
66	First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 181-187.	2.3	28
67	Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a child. <i>Laryngoscope</i> , 2017, 127, 1538-1542.	2.0	47
68	Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. <i>Cancer</i> , 2017, 123, 4914-4923.	4.1	108
69	Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. <i>Clinical Cancer Research</i> , 2017, 23, 6062-6069.	7.0	7
70	Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3215-3221.	1.6	315
71	Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1 advanced, relapsed, or refractory solid tumor or lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 10525-10525.	1.6	11
72	Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways. <i>Oncotarget</i> , 2017, 8, 84697-84713.	1.8	38

#	ARTICLE	IF	CITATIONS
73	Effect of infusion duration on high-dose methotrexate (HDMTX) acute kidney injury (AKI).. Journal of Clinical Oncology, 2017, 35, e22013-e22013.	1.6	0
74	15-0600-Dr. Fox's response to letter to the editor. Cancer Chemotherapy and Pharmacology, 2016, 78, 1099-1100.	2.3	0
75	Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy. International Journal of Pediatric Endocrinology (Springer), 2015, 2015, 3.	1.6	10
76	Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 1562-1566.	1.5	63
77	Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2015, 76, 1273-1283.	2.3	48
78	A 6-Year-Old With Leg Cramps. Pediatrics, 2015, 136, 732-739.	2.1	0
79	Temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukemia (ALL): A Children's Oncology Group study.. Journal of Clinical Oncology, 2015, 33, 10029-10029.	1.6	2
80	An Integrated Service Delivery Model to Identify Persons Living with HIV and to Provide Linkage to HIV Treatment and Care in Prioritized Neighborhoods: A Geotargeted, Program Outcome Study. JMIR Public Health and Surveillance, 2015, 1, e16.	2.6	7
81	Time to disease progression in children with relapsed or refractory neuroblastoma treated with <sc>ABT</sc> 751: A report from the Children's Oncology Group (ANBL0621). Pediatric Blood and Cancer, 2014, 61, 990-996.	1.5	16
82	A liquid chromatography/tandem mass spectrometry method for determination of obatoclox in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 971, 30-34.	2.3	1
83	Historical gold standard for time-to-progression (TTP) and progression-free survival (PFS) from relapsed/refractory neuroblastoma modern era (2002-2014) patients.. Journal of Clinical Oncology, 2014, 32, 10034-10034.	1.6	3
84	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.. Journal of Clinical Oncology, 2014, 32, 10052-10052.	1.6	1
85	A phase I study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children's Oncology Group phase I consortium trial.. Journal of Clinical Oncology, 2014, 32, 10078-10078.	1.6	1
86	A phase 1 study of the c-Met inhibitor tivantinib (ARQ 197, IND#112603) in children with relapsed or refractory solid tumors: A Children's Oncology Group study.. Journal of Clinical Oncology, 2014, 32, 2627-2627.	1.6	3
87	Prospective assessment of renal function using cystatin C and functional MRI in children with newly diagnosed renal tumors.. Journal of Clinical Oncology, 2014, 32, 10053-10053.	1.6	0
88	Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma. Clinical Cancer Research, 2013, 19, 4239-4248.	7.0	136
89	Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist, 2012, 17, 321-e329.	3.7	100
90	Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study.. Journal of Clinical Oncology, 2012, 30, 9500-9500.	1.6	29

#	ARTICLE	IF	CITATIONS
91	Pharmacokinetics (PK) of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.. Journal of Clinical Oncology, 2012, 30, 9576-9576.	1.6	0
92	The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates. Journal of Neuroimmunology, 2010, 223, 138-140.	2.3	44
93	A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan-VEGF Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors. Journal of Clinical Oncology, 2010, 28, 5174-5181.	1.6	98
94	Commentary. Clinical Chemistry, 2010, 56, 1795-1795.	3.2	0